These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23446713)

  • 1. [Bases for the selection of pharmacological treatment in attention deficit hyperactivity disorder].
    Soutullo C; Alvarez-Gomez MJ
    Rev Neurol; 2013 Feb; 56 Suppl 1():S119-29. PubMed ID: 23446713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Update on Current Care guidelines: ADHD (attention-deficit/hyperactivity disorder, children and adolescents)].
    Käypä hoito suosituksen päivitystiivistelmä
    Duodecim; 2012; 128(5):539-40. PubMed ID: 22486070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New options in the pharmacological management of attention-deficit/hyperactivity disorder.
    Olfson M
    Am J Manag Care; 2004 Jul; 10(4 Suppl):S117-24. PubMed ID: 15352538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the 'typical' patient: treating attention-deficit/hyperactivity disorder in preschoolers and adults.
    Vaughan BS; Wetzel MW; Kratochvil CJ
    Int Rev Psychiatry; 2008 Apr; 20(2):143-9. PubMed ID: 18386204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
    Sasané R; Hodgkins P; Meijer W
    Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
    Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
    JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
    Brown RT; Amler RW; Freeman WS; Perrin JM; Stein MT; Feldman HM; Pierce K; Wolraich ML; ;
    Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New therapeutic options in the treatment of attention deficit/hyperactivity disorder].
    Artigas Pallares J
    Rev Neurol; 2004 Feb; 38 Suppl 1():S117-23. PubMed ID: 15011165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
    Kratochvil CJ; Heiligenstein JH; Dittmann R; Spencer TJ; Biederman J; Wernicke J; Newcorn JH; Casat C; Milton D; Michelson D
    J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):776-84. PubMed ID: 12108801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.
    Hazell PL; Kohn MR; Dickson R; Walton RJ; Granger RE; Wyk GW
    J Atten Disord; 2011 Nov; 15(8):674-83. PubMed ID: 20837981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The stimulants.
    Wilens TE; Biederman J
    Psychiatr Clin North Am; 1992 Mar; 15(1):191-222. PubMed ID: 1347939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.